| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Division of Cardiothoracic Surgery, University of Alabama at Birmingham, Birmingham, Alabama
Accepted for publication May 13, 2009.
* Address correspondence to Dr Cerfolio, Division of Cardiothoracic Surgery, University of Alabama at Birmingham, 703 19th St S, ZRB 739, Birmingham, AL 35294 (Email: robert.cerfolio{at}ccc.uab.edu).
Presented at the Forty-fifth Annual Meeting of The Society of Thoracic Surgeons, San Francisco, CA, Jan 26–28, 2009.
Background: Many patients with resected, pathologic (p)stage I non-small cell lung cancer (NSCLC) are not adequately staged preoperatively or intraoperatively. Reported 5-year survival is about 65%. Recently, nonsurgical techniques are being offered to these patients.
Methods: A prospective database was retrospectively reviewed. All patients had an integrated positron-emission tomography/computed tomography (CT) and CT scan, an R0 pulmonary resection with lung palpation, and complete thoracic lymphadenectomy.
Results: From August 2002 until July 2008, 2171 patients presented with presumed, resectable NSCLC. Of these, 721 were clinically (c)staged I, and 1450 were (c)staged II, III, or IV. Of the 721 (c)stage I, 405 (56%) had (p)stage I disease; 101 (14%) were clinically over-staged (benign nodules). Of those with NSCLC, 32% were clinically under-staged (stage II or higher on path). The 5-year Kaplan-Meier survival rates were 80% for (p)stage IA, 72% for (p)stage IB (p = 0.026), and 87% for the 721 with (c)stage I disease. The median-follow up was 3.8 years.
Conclusions: When patients with NCSLC are accurately staged preoperatively and undergo complete thoracic lymphadenectomy, the 5-year survival is 80% for (p)stage IA tumors and 87% for (c)stage I disease. About 32% of patients are under-staged (most commonly from nonimaged N2 disease) despite the liberal application of all of the techniques that assess mediastinal lymph nodes preoperatively. Thus surgical intervention offers improved staging with resection of unsuspected nodal or parenchymal disease. If stereotactic radiation and radiofrequency ablation are considered for patients with clinically staged I NSCLC, these results should be considered.
This article has been cited by other articles:
|
|
 |
|
  S. C. Tomaszek, Y. Kim, S. D. Cassivi, M. R. Jensen, K.-H. R. Shen, F. C. Nichols, C. Deschamps, and D. A. Wigle Bronchial resection margin length and clinical outcome in non-small cell lung cancer Eur J Cardiothorac Surg, November 1, 2011; 40(5): 1151 - 1156. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Cerfolio, A. S. Bryant, and D. J. Minnich Starting a Robotic Program in General Thoracic Surgery: Why, How, and Lessons Learned Ann. Thorac. Surg., June 1, 2011; 91(6): 1729 - 1737. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Cerfolio, A. S. Bryant, M. A. Eloubeidi, P. A. Frederick, D. J. Minnich, K. C. Harbour, and M. T. Dransfield The True False Negative Rates of Esophageal and Endobronchial Ultrasound in the Staging of Mediastinal Lymph Nodes in Patients With Non-Small Cell Lung Cancer Ann. Thorac. Surg., August 1, 2010; 90(2): 427 - 434. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Timmerman Surgery Versus Stereotactic Body Radiation Therapy for Early-Stage Lung Cancer: Who's Down for the Count? J. Clin. Oncol., February 20, 2010; 28(6): 907 - 909. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
